OA10510A - Process and crystal forms of 2-methyl-thieno-benzodiazepine - Google Patents

Process and crystal forms of 2-methyl-thieno-benzodiazepine Download PDF

Info

Publication number
OA10510A
OA10510A OA70082A OA70082A OA10510A OA 10510 A OA10510 A OA 10510A OA 70082 A OA70082 A OA 70082A OA 70082 A OA70082 A OA 70082A OA 10510 A OA10510 A OA 10510A
Authority
OA
OAPI
Prior art keywords
olanzapine
methyl
polymorph
lessthan
disorder
Prior art date
Application number
OA70082A
Other languages
English (en)
Inventor
Charles A Bunnell
Barry A Hendriksen
Samuel D Larsen
Original Assignee
Lilly Co Eli
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10510(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Lilly Industries Ltd filed Critical Lilly Co Eli
Publication of OA10510A publication Critical patent/OA10510A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
OA70082A 1995-03-24 1997-09-24 Process and crystal forms of 2-methyl-thieno-benzodiazepine OA10510A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
OA10510A true OA10510A (en) 2002-04-24

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70082A OA10510A (en) 1995-03-24 1997-09-24 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Country Status (48)

Country Link
US (1) US5736541A (cg-RX-API-DMAC7.html)
EP (3) EP1095941B1 (cg-RX-API-DMAC7.html)
JP (1) JPH11502535A (cg-RX-API-DMAC7.html)
KR (1) KR100399688B1 (cg-RX-API-DMAC7.html)
CN (1) CN1065536C (cg-RX-API-DMAC7.html)
AP (1) AP828A (cg-RX-API-DMAC7.html)
AR (2) AR010448A1 (cg-RX-API-DMAC7.html)
AT (4) AT406771B (cg-RX-API-DMAC7.html)
AU (1) AU706471B2 (cg-RX-API-DMAC7.html)
BG (1) BG62619B1 (cg-RX-API-DMAC7.html)
BR (1) BR9607790A (cg-RX-API-DMAC7.html)
CA (1) CA2214005C (cg-RX-API-DMAC7.html)
CH (1) CH690579A5 (cg-RX-API-DMAC7.html)
CO (1) CO4650278A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ292688B6 (cg-RX-API-DMAC7.html)
DE (4) DE69636313T2 (cg-RX-API-DMAC7.html)
DK (4) DK1095941T3 (cg-RX-API-DMAC7.html)
EA (1) EA000149B1 (cg-RX-API-DMAC7.html)
EE (1) EE03489B1 (cg-RX-API-DMAC7.html)
EG (1) EG23659A (cg-RX-API-DMAC7.html)
ES (3) ES2159346T3 (cg-RX-API-DMAC7.html)
FI (1) FI973750A0 (cg-RX-API-DMAC7.html)
GB (1) GB2313835B (cg-RX-API-DMAC7.html)
HU (1) HU224989B1 (cg-RX-API-DMAC7.html)
IL (1) IL117610A (cg-RX-API-DMAC7.html)
IS (1) IS1896B (cg-RX-API-DMAC7.html)
LT (1) LT4349B (cg-RX-API-DMAC7.html)
LU (1) LU90096B1 (cg-RX-API-DMAC7.html)
LV (1) LV12018B (cg-RX-API-DMAC7.html)
MY (1) MY114701A (cg-RX-API-DMAC7.html)
NO (1) NO314663B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ306110A (cg-RX-API-DMAC7.html)
OA (1) OA10510A (cg-RX-API-DMAC7.html)
PA (1) PA8353701A1 (cg-RX-API-DMAC7.html)
PE (1) PE44897A1 (cg-RX-API-DMAC7.html)
PL (1) PL183723B1 (cg-RX-API-DMAC7.html)
PT (3) PT1445259E (cg-RX-API-DMAC7.html)
RO (1) RO118872B1 (cg-RX-API-DMAC7.html)
SE (1) SE9703205L (cg-RX-API-DMAC7.html)
SI (4) SI0733635T1 (cg-RX-API-DMAC7.html)
SK (1) SK284143B6 (cg-RX-API-DMAC7.html)
SV (1) SV1996000031A (cg-RX-API-DMAC7.html)
TR (1) TR199701017T1 (cg-RX-API-DMAC7.html)
TW (2) TW513432B (cg-RX-API-DMAC7.html)
UA (1) UA44765C2 (cg-RX-API-DMAC7.html)
WO (1) WO1996030375A1 (cg-RX-API-DMAC7.html)
YU (1) YU49478B (cg-RX-API-DMAC7.html)
ZA (2) ZA962342B (cg-RX-API-DMAC7.html)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
JPH11512705A (ja) * 1995-09-29 1999-11-02 イーライ・リリー・アンド・カンパニー チック症を処置する方法
CZ290198A3 (cs) * 1996-03-11 1999-09-15 Eli Lilly And Company Farmaceutický prostředek pro ošetřování nespavosti
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
PL329217A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Pain relieving method
CA2250155A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
BR9708145A (pt) * 1996-03-25 1999-07-27 Lilly Co Eli Processo para tratamento de dor de enxaqueca
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
AU720366B2 (en) * 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
EP1155696B1 (en) * 1997-04-15 2004-03-03 Eli Lilly And Company Use of olanzapine for the manufacture of a medicament for neuroprotection
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
AU759751B2 (en) * 1998-09-30 2003-05-01 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
PT1246827E (pt) * 1999-12-28 2005-08-31 Cipla Ltd Novas formas polimerficas da olanzapina
CA2420987A1 (en) * 2000-08-31 2002-03-07 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
CH695862A5 (fr) 2001-12-24 2006-09-29 Sun Pharmaceutical Ind Ltd Forme cristalline I de la methyl-4-(4-methyl-1-piperazinyl) 10H-thieno [2,3-b] [1,5] benzodiazepine.
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
IL163846A0 (en) * 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
JP2007511605A (ja) * 2003-11-18 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オランザピン含有経皮薬物送達組成物
WO2005063771A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries Ltd Methods of preparing olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
ES2303462B1 (es) * 2004-09-06 2009-06-05 Shasun Chemicals And Drugs Limited Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
EP1838716B1 (en) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
EP1863775A4 (en) * 2005-03-21 2009-11-11 Reddys Lab Ltd Dr PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM I OF OLANZAPINE
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
EP2608670B1 (en) 2010-08-23 2018-10-31 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
ES3057437T3 (en) 2012-08-21 2026-03-02 Janssen Pharmaceutica Nv Antibodies to olanzapine haptens and use thereof
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
KR20240130825A (ko) 2022-01-20 2024-08-29 테바 파마슈티컬스 인터내셔널 게엠베하 올란자핀, 이의 조성물 및 이의 사용 방법
CA3266264A1 (en) 2023-01-10 2024-07-18 Medincell Sa OLANZAPINE COMPOSITIONS AND METHODS OF USE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
DE69329887T2 (de) * 1992-05-29 2001-05-23 Eli Lilly And Co., Ltd. Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
DK1445259T3 (da) 2006-10-16
YU17796A (sh) 1999-03-04
SI1445259T1 (sl) 2006-10-31
JPH11502535A (ja) 1999-03-02
YU49478B (sh) 2006-05-25
EP1095941B1 (en) 2003-10-08
BR9607790A (pt) 1998-07-07
KR19980703188A (ko) 1998-10-15
DE69614426D1 (de) 2001-09-20
DE69614426T2 (de) 2002-05-23
RO118872B1 (ro) 2003-12-30
EP0733635B1 (en) 2001-08-16
AP828A (en) 2000-04-28
EA000149B1 (ru) 1998-10-29
PL322501A1 (en) 1998-02-02
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
AU5427996A (en) 1996-10-16
EP0733635A1 (en) 1996-09-25
LT4349B (lt) 1998-05-25
IS4564A (is) 1997-09-22
EA199700262A1 (ru) 1998-02-26
TW513432B (en) 2002-12-11
DK0733635T3 (da) 2001-10-08
CN1065536C (zh) 2001-05-09
SI9620040B (sl) 2002-02-28
HU224989B1 (en) 2006-05-29
EP1445259B1 (en) 2006-06-28
FI973750A7 (fi) 1997-09-22
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
PT1095941E (pt) 2004-02-27
HUP9802824A2 (hu) 1999-06-28
CZ300097A3 (en) 1997-12-17
DK108997A (da) 1997-11-12
TR199701017T1 (xx) 1998-01-21
SI9620040A (sl) 1998-06-30
MX9707183A (es) 1997-11-29
FI973750L (fi) 1997-09-22
NO314663B1 (no) 2003-04-28
HUP9802824A3 (en) 2000-01-28
EE03489B1 (et) 2001-08-15
ES2159346T3 (es) 2001-10-01
SE9703205D0 (sv) 1997-09-05
EE9700232A (et) 1998-04-15
NZ306110A (en) 1998-09-24
SV1996000031A (es) 1998-03-27
DE69630324D1 (de) 2003-11-13
ES2266719T3 (es) 2007-03-01
BG101900A (en) 1999-03-31
CZ292688B6 (cs) 2003-11-12
BG62619B1 (bg) 2000-03-31
PT733635E (pt) 2001-12-28
ZA962342B (en) 1997-09-22
SI1095941T1 (en) 2003-12-31
IS1896B (is) 2003-10-20
PL183723B1 (pl) 2002-07-31
IL117610A0 (en) 1996-07-23
GB2313835B (en) 1998-09-16
SK121897A3 (en) 1998-03-04
SK284143B6 (sk) 2004-10-05
DE69636313D1 (de) 2006-08-10
DE19681286T1 (de) 1998-04-02
ATA902196A (de) 2000-01-15
FI973750A0 (fi) 1997-09-22
KR100399688B1 (ko) 2004-02-18
SI0733635T1 (en) 2002-06-30
ATE251627T1 (de) 2003-10-15
PE44897A1 (es) 1997-10-22
LU90096B1 (fr) 1997-07-22
EP1445259A1 (en) 2004-08-11
ES2208220T3 (es) 2004-06-16
DK1095941T3 (da) 2004-02-16
NO974365L (no) 1997-09-22
SE9703205L (sv) 1997-09-05
CA2214005A1 (en) 1996-10-03
HK1013988A1 (en) 1999-09-17
EG23659A (en) 2007-03-26
TW442488B (en) 2001-06-23
CN1179160A (zh) 1998-04-15
ATE204280T1 (de) 2001-09-15
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
US5736541A (en) 1998-04-07
AR002719A1 (es) 1998-04-29
CH690579A5 (de) 2000-10-31
ATE331719T1 (de) 2006-07-15
CO4650278A1 (es) 1998-09-03
MY114701A (en) 2002-12-31
AU706471B2 (en) 1999-06-17
ZA962344B (en) 1997-09-22
GB2313835A (en) 1997-12-10
CA2214005C (en) 2001-07-03
LV12018A (lv) 1998-04-20
AT406771B (de) 2000-08-25
DE69636313T2 (de) 2007-05-31
IL117610A (en) 2001-08-26
EP1095941A1 (en) 2001-05-02
GB9719819D0 (en) 1997-11-19
UA44765C2 (uk) 2002-03-15
DE69630324T2 (de) 2004-07-29
LT97148A (lt) 1998-01-26
LV12018B (en) 1998-09-20

Similar Documents

Publication Publication Date Title
CA2214005C (en) Process and crystal forms of 2-methyl-thieno-benzodiazepine
AU720366B2 (en) Olanzapine dihydrate D
AU719441B2 (en) Intermediates and process for preparing olanzapine
HK1013988B (en) Crystal forms of a thieno(2,3-b)(1,5) benzodiazepine derivative and process for their preparation
MXPA97007183A (en) A process and glass forms of 2-methyl-tieno-benzodiazep
HK1009809B (en) Olanzapine dihydrate d
HK1009807B (en) Intermediates and process for preparing olanzapine
MXPA98007430A (en) Medications for the treatment of the car